Rhumbline Advisers Has $2.16 Million Position in Teladoc Health, Inc. $TDOC

Rhumbline Advisers lowered its holdings in Teladoc Health, Inc. (NYSE:TDOCFree Report) by 3.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 271,434 shares of the health services provider’s stock after selling 9,986 shares during the quarter. Rhumbline Advisers owned about 0.15% of Teladoc Health worth $2,161,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Strs Ohio purchased a new position in Teladoc Health during the 1st quarter worth $349,000. Acadian Asset Management LLC purchased a new position in shares of Teladoc Health in the 1st quarter worth about $615,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Teladoc Health by 5.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock worth $3,566,000 after buying an additional 24,124 shares during the last quarter. NewEdge Advisors LLC boosted its holdings in shares of Teladoc Health by 1,278.7% in the 1st quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock worth $90,000 after buying an additional 10,485 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Teladoc Health by 2.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock worth $1,542,000 after purchasing an additional 5,235 shares during the period. 76.82% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health Price Performance

Shares of TDOC stock opened at $7.90 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.67 and a quick ratio of 2.58. The company has a market cap of $1.40 billion, a P/E ratio of -6.64 and a beta of 1.84. The stock’s 50-day moving average is $7.67 and its 200 day moving average is $7.66. Teladoc Health, Inc. has a 1-year low of $6.35 and a 1-year high of $15.21.

Teladoc Health (NYSE:TDOCGet Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The health services provider reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.08. The firm had revenue of $631.90 million during the quarter, compared to analysts’ expectations of $621.91 million. Teladoc Health had a negative return on equity of 10.13% and a negative net margin of 8.16%.The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period last year, the business posted ($0.38) earnings per share. Teladoc Health has set its Q3 2025 guidance at -0.350–0.200 EPS. FY 2025 guidance at -1.350–1.000 EPS. Research analysts predict that Teladoc Health, Inc. will post -1.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

TDOC has been the topic of a number of recent analyst reports. Evercore ISI increased their price target on shares of Teladoc Health from $7.00 to $8.00 and gave the stock an “in-line” rating in a report on Wednesday, July 9th. Truist Financial reduced their price target on shares of Teladoc Health from $10.00 to $9.00 and set a “hold” rating on the stock in a research report on Tuesday, May 27th. Bank of America reduced their price target on shares of Teladoc Health from $8.00 to $7.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 28th. Finally, Mizuho began coverage on shares of Teladoc Health in a research report on Friday, July 25th. They set a “neutral” rating and a $10.00 price target on the stock. Six analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $9.80.

View Our Latest Stock Report on Teladoc Health

About Teladoc Health

(Free Report)

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.

Further Reading

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health, Inc. (NYSE:TDOCFree Report).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.